{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:40:23Z","timestamp":1761896423367,"version":"3.37.3"},"reference-count":26,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2016,11,27]],"date-time":"2016-11-27T00:00:00Z","timestamp":1480204800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"},{"start":{"date-parts":[[2016,11,27]],"date-time":"2016-11-27T00:00:00Z","timestamp":1480204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical Research Council and the National Institute for Health Research (NIHR)"},{"DOI":"10.13039\/501100006751","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Salud Mental","doi-asserted-by":"publisher","award":["(MR\/J002178\/1)"],"award-info":[{"award-number":["(MR\/J002178\/1)"]}],"id":[{"id":"10.13039\/501100006751","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["wiley.com"],"crossmark-restriction":true},"short-container-title":["Statist. Med."],"published-print":{"date-parts":[[2017,2,28]]},"DOI":"10.1002\/sim.7169","type":"journal-article","created":{"date-parts":[[2016,11,28]],"date-time":"2016-11-28T02:22:46Z","timestamp":1480299766000},"page":"754-771","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Developing a Bayesian adaptive design for a phase I clinical trial: a case study for a novel HIV treatment"],"prefix":"10.1002","volume":"36","author":[{"given":"Alexina J.","family":"Mason","sequence":"first","affiliation":[{"name":"Department of Health Services Research and Policy; London School of Hygiene and Tropical Medicine; 15-17 Tavistock Place London WC1H 9SH U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Gonzalez-Maffe","sequence":"additional","affiliation":[{"name":"Imperial Clinical Trials Unit; Imperial College London; 68 Wood Lane London W12 7RH U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Killian","family":"Quinn","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Department of Medicine; Imperial College London; London W2 1PG U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicki","family":"Doyle","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Department of Medicine; Imperial College London; London W2 1PG U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Legg","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Department of Medicine; Imperial College London; London W2 1PG U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Norsworthy","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Department of Medicine; Imperial College London; London W2 1PG U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy","family":"Trevelion","sequence":"additional","affiliation":[{"name":"HIV i-Base"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Winston","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Department of Medicine; Imperial College London; London W2 1PG U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3146-7466","authenticated-orcid":false,"given":"Deborah","family":"Ashby","sequence":"additional","affiliation":[{"name":"Imperial Clinical Trials Unit; Imperial College London; 68 Wood Lane London W12 7RH U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,11,27]]},"reference":[{"key":"10.1002\/sim.7169-BIB0001|sim7169-cit-0001","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2307\/2531693","article-title":"Design and analysis of phase I clinical trials","volume":"45","author":"Storer","year":"1989","journal-title":"Biometrics"},{"key":"10.1002\/sim.7169-BIB0002|sim7169-cit-0002","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djp079","article-title":"Dose escalation methods in phase I cancer clinical trials","volume":"101","author":"Le Tourneau","year":"2009","journal-title":"Journal of the National Cancer Institute"},{"volume-title":"Bayesian Adaptive Methods for Clinical Trials","year":"2011","author":"Berry","key":"10.1002\/sim.7169-BIB0003|sim7169-cit-0003"},{"key":"10.1002\/sim.7169-BIB0004|sim7169-cit-0004","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2307\/2531628","article-title":"Continual reassessment method: a practical design for phase 1 clinical trials in cancer","volume":"46","author":"O'Quigley","year":"1990","journal-title":"Biometrics"},{"key":"10.1002\/sim.7169-BIB0005|sim7169-cit-0005","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1002\/sim.4780131802","article-title":"A comparison of two phase I trial designs","volume":"13","author":"Korn","year":"1994","journal-title":"Statistics in Medicine"},{"key":"10.1002\/sim.7169-BIB0006|sim7169-cit-0006","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/10543409408835079","article-title":"Practical modifications of the continual reassessment method for phase I cancer clinical trials","volume":"4","author":"Faries","year":"1994","journal-title":"Journal of Biopharmaceutical Statistics"},{"key":"10.1002\/sim.7169-BIB0007|sim7169-cit-0007","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/(SICI)1097-0258(19980530)17:10<1103::AID-SIM793>3.0.CO;2-9","article-title":"Cancer phase I clinical trials: efficient dose escalation with overdose control","volume":"17","author":"Babb","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/sim.7169-BIB0008|sim7169-cit-0008","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1159\/000228709","article-title":"High-dose Lovastatin for acute ischemic stroke: results of the phase I dose escalation neuroprotection with statin therapy for acute recovery trial (NeuSTART)","volume":"28","author":"Elkind","year":"2009","journal-title":"Cerebrovascular Diseases"},{"key":"10.1002\/sim.7169-BIB0009|sim7169-cit-0009","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/1745-6215-13-145","article-title":"Adaptive trial designs: a review of barriers and opportunities","volume":"13","author":"Kairalla","year":"2012","journal-title":"Trials"},{"key":"10.1002\/sim.7169-BIB0010|sim7169-cit-0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/sim.2303","article-title":"A Bayesian dose finding design for dual endpoint phase I trials","volume":"25","author":"Loke","year":"2006","journal-title":"Statistics in Medicine"},{"key":"10.1002\/sim.7169-BIB0011|sim7169-cit-0011","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1191\/1740774505cn094oa","article-title":"ASTIN: A Bayesian adaptive dose-response trial in acute stroke","volume":"2","author":"Grieve","year":"2005","journal-title":"Clinical Trials"},{"key":"10.1002\/sim.7169-BIB0012|sim7169-cit-0012","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/j.0006-341X.2001.01018.x","article-title":"Dose-finding designs for HIV studies","volume":"57","author":"O'Quigley","year":"2001","journal-title":"Biometrics"},{"key":"10.1002\/sim.7169-BIB0013|sim7169-cit-0013","unstructured":"http:\/\/www.unaids.org\/en\/dataanalysis\/datatools\/aidsinfo\/.,J.U.N.P.o.H.A.U.A"},{"key":"10.1002\/sim.7169-BIB0014|sim7169-cit-0014","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1097\/00002030-199910010-00018","article-title":"The practical significance of potential biases in estimates of the AIDS incubation periods distribution in the UK Register of HIV Seroconverters","volume":"13","author":"Porter","year":"1999","journal-title":"AIDS"},{"key":"10.1002\/sim.7169-BIB0015|sim7169-cit-0015","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jama.300.1.51","article-title":"Changes in the risk of death after HIV seroconversion compared with mortality in the general population","volume":"300","author":"Bhaskaran","year":"2008","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/sim.7169-BIB0016|sim7169-cit-0016","doi-asserted-by":"crossref","first-page":"d6016","DOI":"10.1136\/bmj.d6016","article-title":"Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK collaborative HIV Cohort (UK CHIC) study","volume":"343","author":"May","year":"2011","journal-title":"BMJ"},{"key":"10.1002\/sim.7169-BIB0017|sim7169-cit-0017","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/cid\/cir626","article-title":"Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study","volume":"53","author":"Hasse","year":"2011","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/sim.7169-BIB0018|sim7169-cit-0018","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1517\/17425255.2013.781153","article-title":"Clinical pharmacokinetics of antiretroviral drugs in older persons","volume":"9","author":"Schoen","year":"2013","journal-title":"Expert Opinion on Drug Metabolism & Toxicology"},{"key":"10.1002\/sim.7169-BIB0019|sim7169-cit-0019","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0149-2918(04)90032-X","article-title":"Enfuvirtide: a fusion inhibitor for the treatment of HIV infection","volume":"26","author":"Fung","year":"2004","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/sim.7169-BIB0020|sim7169-cit-0020","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.1073\/pnas.0901007106","article-title":"Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency","volume":"106","author":"Ingallinella","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1002\/sim.7169-BIB0021|sim7169-cit-0021","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1177\/1740774508098788","article-title":"Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomes","volume":"5","author":"Resche-Rigon","year":"2008","journal-title":"Clinical trials"},{"key":"10.1002\/sim.7169-BIB0022|sim7169-cit-0022","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1191\/1740774506cn134oa","article-title":"The continual reassessment method for dose-finding studies: a tutorial","volume":"3","author":"Garrett-Mayer","year":"2006","journal-title":"Clinical trials"},{"key":"10.1002\/sim.7169-BIB0023|sim7169-cit-0023","unstructured":"R Core Team R: a language and environment for statistical computing R Foundation for Statistical Computing Vienna, Austria, 2013 http:\/\/www.R-project.org"},{"key":"10.1002\/sim.7169-BIB0024|sim7169-cit-0024","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1023\/A:1008929526011","article-title":"Bayesian modelling framework: concepts, structure, and extensibility","volume":"10","author":"Lunn","year":"2000","journal-title":"Statistics and Computing"},{"key":"10.1002\/sim.7169-BIB0025|sim7169-cit-0025","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1002\/sim.3680","article-title":"The BUGS project: evolution, critique and future directions","volume":"28","author":"Lunn","year":"2009","journal-title":"Statistics in Medicine"},{"key":"10.1002\/sim.7169-BIB0026|sim7169-cit-0026","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1080\/10543406.2011.582972","article-title":"Bayesian continual reassessment method for dose-finding trials infusing T cells with limited sample size","volume":"22","author":"Ji","year":"2012","journal-title":"Journal of Biopharmaceutical Statistics"}],"container-title":["Statistics in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fsim.7169","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/sim.7169","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T06:57:38Z","timestamp":1625381858000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/sim.7169"}},"subtitle":["Bayesian adaptive design for a phase I clinical trial: case study"],"short-title":[],"issued":{"date-parts":[[2016,11,27]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,2,28]]}},"URL":"https:\/\/doi.org\/10.1002\/sim.7169","archive":["Portico"],"relation":{},"ISSN":["0277-6715"],"issn-type":[{"type":"print","value":"0277-6715"}],"subject":[],"published":{"date-parts":[[2016,11,27]]}}}